2024-03-22 09:18 | UU:CBAY | | News Release200 | Gilead Sciences Announces Completion of Acquisition of CymaBay |
2024-03-04 08:00 | UU:CBAY | | News Release200 | CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis |
2024-02-28 16:45 | UU:CBAY | | News Release200 | CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update |
2024-02-21 17:43 | UU:CBAY | | News Release200 | The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis |
2024-02-20 16:05 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2024-02-12 08:45 | UU:CBAY | | News Release200 | CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis |
2024-02-12 08:30 | UU:CBAY | | News Release200 | Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics |
2024-01-31 08:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Participate in Upcoming Investment Conferences |
2024-01-16 16:29 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2024-01-03 08:00 | UU:CBAY | | News Release200 | New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar |
2024-01-02 08:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024 |
2023-12-18 16:05 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-12-15 08:00 | UU:CBAY | | News Release200 | CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis |
2023-11-17 16:15 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-11-13 08:00 | UU:CBAY | | News Release200 | CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting ‚ ® |
2023-11-07 16:04 | UU:CBAY | | News Release200 | CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update |
2023-11-06 08:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Present at Upcoming Investment Conferences |
2023-11-01 08:00 | UU:CBAY | | News Release200 | CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis |
2023-10-31 16:05 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023 |
2023-10-23 16:05 | UU:CBAY | | News Release200 | CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023 |
2023-10-23 08:00 | UU:CBAY | | News Release200 | Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis |
2023-10-18 08:00 | UU:CBAY | | News Release200 | CymaBay ¢ € ™s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting ‚ ® 2023 |
2023-10-16 16:05 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-09-21 08:00 | UU:CBAY | | News Release200 | CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis |
2023-09-15 08:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference |
2023-09-14 16:58 | UU:CBAY | | News Release200 | CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares |
2023-09-11 22:15 | UU:CBAY | | News Release200 | CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants |
2023-09-11 06:00 | UU:CBAY | | News Release200 | CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants |
2023-09-07 07:00 | UU:CBAY | | News Release200 | CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis |
2023-09-06 16:05 | UU:CBAY | | News Release200 | CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023 |
2023-08-28 16:29 | UU:CBAY | | News Release200 | CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-08-10 16:04 | UU:CBAY | | News Release200 | CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update |
2023-08-10 08:00 | UU:CBAY | | News Release200 | CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase |
2023-08-03 16:05 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023 |
2023-06-21 03:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels |
2023-06-07 02:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress ¢ „ ¢ 2023 |
2023-05-15 16:04 | UU:CBAY | | News Release200 | CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update |
2023-05-10 08:00 | UU:CBAY | | News Release200 | CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023 |
2023-05-09 08:00 | UU:CBAY | | News Release200 | CymaBay Names Harish Shantharam Chief Financial Officer |